Skip to main
LUNG
LUNG logo

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 40%
Sell 10%
Strong Sell 0%

Bulls say

Pulmonx Corp reported a total revenue of $83.8 million for the full year 2024, marking a 22% increase from the previous year, with notably strong performance stemming from both domestic and international sales. The company's quarterly revenue in Q4 2024 reached a record $23.8 million, reflecting a 23% growth year-over-year, indicating robust demand for its innovative medical solutions. Additionally, the expansion of reimbursement coverage and advancements in patient selection technology are projected to enhance adoption rates and market penetration, further solidifying Pulmonx's positive growth outlook in the medical device sector.

Bears say

Pulmonx Corp reported a gross profit of $17.6 million for the quarter, reflecting a slight decrease in gross margin to 74%, indicating potential pressures on profitability. The company's cash reserves decreased to $101.5 million, suggesting a potential concern over liquidity as expenses rise and cash flow stability is questioned. Additionally, the company's exposure to the small capital market increases volatility and risk, which could deter potential investors amid the broader market challenges posed by the healthcare industry's evolving dynamics and unmet medical needs.

Pulmonx (LUNG) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 40% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 10 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Sep 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.